K
Kyu Yeon Hur
Researcher at Samsung Medical Center
Publications - 156
Citations - 5041
Kyu Yeon Hur is an academic researcher from Samsung Medical Center. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 32, co-authored 142 publications receiving 4008 citations. Previous affiliations of Kyu Yeon Hur include Yonsei University & Harvard University.
Papers
More filters
Journal ArticleDOI
Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine
Kook Hwan Kim,Yeon Taek Jeong,Hyunhee Oh,Seonghun Kim,Jae Min Cho,Yo-Na Kim,Su Sung Kim,Dohoon Kim,Kyu Yeon Hur,Hyoung Kyu Kim,Tae-Hee Ko,Jin Han,Hong Lim Kim,Jin Kim,Sung Hoon Back,Masaaki Komatsu,Hsiuchen Chen,David C. Chan,Morichika Konishi,Nobuyuki Itoh,Cheol Soo Choi,Myung-Shik Lee,Myung-Shik Lee +22 more
TL;DR: It is suggested that autophagy deficiency and subsequent mitochondrial dysfunction promote Fgf21 expression, a hormone the authors consequently term a 'mitokine', and together these processes promote protection from diet-induced obesity and insulin resistance.
Journal ArticleDOI
Silencing of Lipid Metabolism Genes through IRE1α-Mediated mRNA Decay Lowers Plasma Lipids in Mice
Jae-Seon So,Kyu Yeon Hur,Margarite L. Tarrio,Vera M. Ruda,Maria Frank-Kamenetsky,Kevin Fitzgerald,Victor Koteliansky,Andrew H. Lichtman,Takao Iwawaki,Takao Iwawaki,Laurie H. Glimcher,Laurie H. Glimcher,Ann-Hwee Lee +12 more
TL;DR: Comprehensive microarray analysis of XBP1 and/or IRE1α-deficient liver identified genes involved in lipogenesis and lipoprotein metabolism as RIDD substrates, which might contribute to the suppression of plasma lipid levels by activated I RE1α.
Journal ArticleDOI
Gut Microbiota and Metabolic Disorders
Kyu Yeon Hur,Myung-Shik Lee +1 more
TL;DR: Several strategies have been developed to change gut microbiota such as prebiotics, probiotics, certain antidiabetic drugs or fecal microbiota transplantation, which have diverse effects on body metabolism and on the development of metabolic disorders.
Journal ArticleDOI
Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic diseases
Soo Kyung Kim,Hae Jin Kim,Kyu Yeon Hur,Sung Hee Choi,Chul Woo Ahn,Sung Kil Lim,Kyung Rae Kim,Hyun Chul Lee,Kap Bum Huh,Bong Soo Cha +9 more
TL;DR: VFT might be a reliable index for assessing the amount of visceral fat and for identifying diabetic patients, particularly men, who are at high risk of cardiovascular disease and metabolic diseases.
Journal ArticleDOI
2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
Mee Kyoung Kim,Seung Hyun Ko,Bo-Yeon Kim,Eun Seok Kang,Jung Hyun Noh,Soo Kyung Kim,Seok O Park,Kyu Yeon Hur,Suk Chon,Min Kyong Moon,Nan Hee Kim,Sang Yong Kim,Sang Youl Rhee,Kang Woo Lee,Jae Hyeon Kim,Eun-Jung Rhee,SungWan Chun,Sung Hoon Yu,Dae Jung Kim,Hyuk-Sang Kwon,Kyong Soo Park,Kyong Soo Park +21 more
TL;DR: Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM and evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2 DM were incorporated into the recommendations.